Lasco, Chessan A.

HRN: 29-39-00  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/27/2026
CO-AMOXICLAV 625MG (TAB)
07/27/2026
08/02/2026
PO
625MG/TAB
Q8H
MULTIPLE SOFT TISSUE INJURIES
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: